Amyris (NASDAQ:AMRS) Upgraded by BidaskClub to “Hold”

BidaskClub upgraded shares of Amyris (NASDAQ:AMRS) from a sell rating to a hold rating in a research report released on Tuesday morning, BidAskClub reports.

Separately, HC Wainwright reissued a buy rating and issued a $11.00 target price on shares of Amyris in a research note on Friday, October 11th.

AMRS stock opened at $3.94 on Tuesday. The stock’s 50 day moving average price is $3.83 and its 200 day moving average price is $3.79. Amyris has a 1 year low of $1.87 and a 1 year high of $6.06.

Amyris (NASDAQ:AMRS) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.51) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.53) by $0.02. The company had revenue of $34.95 million for the quarter, compared to analyst estimates of $21.60 million. Analysts expect that Amyris will post -2.3 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in AMRS. Vivo Capital LLC raised its holdings in Amyris by 16.4% in the second quarter. Vivo Capital LLC now owns 6,490,557 shares of the biotechnology company’s stock valued at $23,106,000 after acquiring an additional 914,772 shares in the last quarter. BlackRock Inc. grew its holdings in Amyris by 15.2% during the second quarter. BlackRock Inc. now owns 3,709,099 shares of the biotechnology company’s stock worth $13,204,000 after acquiring an additional 488,491 shares during the period. Vanguard Group Inc. raised its position in Amyris by 15.9% in the second quarter. Vanguard Group Inc. now owns 2,373,116 shares of the biotechnology company’s stock worth $8,448,000 after acquiring an additional 325,775 shares in the last quarter. Allianz Asset Management GmbH raised its position in Amyris by 66.9% in the second quarter. Allianz Asset Management GmbH now owns 1,053,712 shares of the biotechnology company’s stock worth $3,751,000 after acquiring an additional 422,362 shares in the last quarter. Finally, State Street Corp raised its position in Amyris by 5.5% in the third quarter. State Street Corp now owns 669,921 shares of the biotechnology company’s stock worth $3,189,000 after acquiring an additional 35,126 shares in the last quarter. 22.45% of the stock is currently owned by institutional investors.

About Amyris

Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products.

Recommended Story: What is a balanced fund?

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.